Next Article in Journal
VDAC1 Intervention Alleviates Bisphenol AF-Induced Succinate Metabolism Dysregulation and Inflammatory Responses
Previous Article in Journal
Synthesis and Anticancer Activity Evaluation of New 5-((5-Nitrofuran-2-yl)allylidene)-2-thioxo-4-thiazolidinones
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Article

Synthesis of Novel Chloro-Benzo [d]imidazole Regioisomers as Selective CB2 Receptor Agonists: Indirect Functional Evaluation and Molecular Insights

by
Valeria Zuñiga Salazar
1,
Renato Burgos Ravanal
2,
Jonathan Soto-Flores
1,
Gianfranco Sabadini
3,
José Vicente González
2,
Jaime Mella
3,4,* and
Javier Romero-Parra
1,*
1
Departamento de Química Orgánica y Fisicoquímicas, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Olivos 1007, Santiago 8380544, Chile
2
School of Pharmacy, Faculty of Chemistry and Pharmacy, Pontificia Universidad Católica de Chile, Vicuña Mackenna 4860, Santiago 7820436, Chile
3
Instituto de Química, Facultad de Ciencias, Universidad de Valparaíso, Av. Gran Bretaña 1111, Valparaíso 2360102, Chile
4
Centro de Investigacion, Desarrollo e Innovacion de Productos Bioactivos (CInBIO), Universidad de Valparaiso, Av. Gran Bretaña 1111, Valparaíso 2360102, Chile
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(11), 1599; https://doi.org/10.3390/ph18111599
Submission received: 5 September 2025 / Revised: 5 October 2025 / Accepted: 20 October 2025 / Published: 22 October 2025
(This article belongs to the Section Medicinal Chemistry)

Abstract

Background/Objectives: The cannabinoid type 2 receptor (CB2 receptor) has been extensively studied in recent years due to the benefits associated with its modulation, including the regulation of the inflammatory response, neuroimmunomodulatory properties, and antitumor effects, all with the advantage of lacking significant psychoactive effects. Herein, we report the design, synthesis, characterization, biological assays, and molecular modelling analyses of novel (5/6-chloro-2-aryl-1H-benzo [d]imidazol-1-yl)(4-methoxyphenyl)methanone and 5/6-chloro-1-(4-methoxybenzyl)-2-aryl-1H-benzo [d]imidazole regioisomers as potential cannabinoid type 2 receptor ligands. Methods: The compounds were evaluated for their presumed CB2 agonist activity using an indirect receptor-dependent apoptotic cell death assay exerted by cannabinoids, using the cell lines HEK293 (low CB1/CB2 expression), U-87 MG (high CB1 expression), and HL-60 (exclusive CB2 expression), and including the known cannabinoid ligands WIN-55,212-2 and AM630 as reference ligands. Flow cytometry was performed to assess apoptosis. Molecular docking and molecular dynamics simulations were used to explore ligand-receptor interactions at the CB2 active site. Results: Compounds 3a, 3b’, 3c, and 4b selectively reduced HL-60 cell viability, similar to WIN-55,212-2, while showing no toxicity toward HEK293 or U-87 MG cells. Flow cytometry indicated that compounds 3a and 3c induced apoptosis in HL-60 cells comparable to WIN-55,212-2. Computational studies suggested that both compounds bind within the CB2 receptor active site predominantly through π–π and hydrophobic interactions involving their benzo [d]imidazole cores, 2-aryl moieties, and 4-methoxybenzoyl scaffolds, resembling the binding patterns of established CB2 ligands. Conclusions: Compounds 3a and 3c exert selective cytotoxicity against HL-60 cells, likely via a CB2 agonist-mediated apoptotic mechanism. The applied combined experimental and computational approach provides a rapid, informative strategy for preliminary evaluation of CB2 ligands and guides subsequent detailed pharmacological studies.
Keywords: cannabinoids; benzo [d]imidazole; cytotoxic studies; flow cytometry; indirect agonism; docking; molecular dynamics cannabinoids; benzo [d]imidazole; cytotoxic studies; flow cytometry; indirect agonism; docking; molecular dynamics
Graphical Abstract

Share and Cite

MDPI and ACS Style

Salazar, V.Z.; Ravanal, R.B.; Soto-Flores, J.; Sabadini, G.; González, J.V.; Mella, J.; Romero-Parra, J. Synthesis of Novel Chloro-Benzo [d]imidazole Regioisomers as Selective CB2 Receptor Agonists: Indirect Functional Evaluation and Molecular Insights. Pharmaceuticals 2025, 18, 1599. https://doi.org/10.3390/ph18111599

AMA Style

Salazar VZ, Ravanal RB, Soto-Flores J, Sabadini G, González JV, Mella J, Romero-Parra J. Synthesis of Novel Chloro-Benzo [d]imidazole Regioisomers as Selective CB2 Receptor Agonists: Indirect Functional Evaluation and Molecular Insights. Pharmaceuticals. 2025; 18(11):1599. https://doi.org/10.3390/ph18111599

Chicago/Turabian Style

Salazar, Valeria Zuñiga, Renato Burgos Ravanal, Jonathan Soto-Flores, Gianfranco Sabadini, José Vicente González, Jaime Mella, and Javier Romero-Parra. 2025. "Synthesis of Novel Chloro-Benzo [d]imidazole Regioisomers as Selective CB2 Receptor Agonists: Indirect Functional Evaluation and Molecular Insights" Pharmaceuticals 18, no. 11: 1599. https://doi.org/10.3390/ph18111599

APA Style

Salazar, V. Z., Ravanal, R. B., Soto-Flores, J., Sabadini, G., González, J. V., Mella, J., & Romero-Parra, J. (2025). Synthesis of Novel Chloro-Benzo [d]imidazole Regioisomers as Selective CB2 Receptor Agonists: Indirect Functional Evaluation and Molecular Insights. Pharmaceuticals, 18(11), 1599. https://doi.org/10.3390/ph18111599

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop